In one of the biggest global health breakthroughs of 2025, pharmaceutical company Novartis announced that GanLum, a novel malaria treatment, achieved a remarkable 99.2% cure rate in phase 3 clinical trials — outperforming the standard treatment's 96.7% rate. The drug represents the first new class of malaria medication in decades and is now seeking regulatory approval.
Malaria still kills over 600,000 people annually, the vast majority of them children under five in sub-Saharan Africa. A more effective treatment could save hundreds of thousands of lives each year. "This could be transformative for the countries hardest hit by malaria," said a WHO spokesperson. The drug's simplified dosing regimen also makes it easier to administer in rural areas with limited healthcare infrastructure.
“2% cure rate in phase 3 clinical trials — outperforming the standard treatment's 96.”
How did this story make you feel?
📎 Cite this article
Good News Good Vibes. (2025, December 22). New Malaria Drug GanLum Achieves 99.2% Cure Rate in Clinical Trials. Retrieved from https://goodnewsgoodvibes.com/en/article/ganlum-malaria-treatment-99-percent-cure-rate-2025
https://goodnewsgoodvibes.com/en/article/ganlum-malaria-treatment-99-percent-cure-rate-2025
Editorial Team
Our editorial team curates and verifies positive news from credible sources worldwide.
Last reviewed: December 22, 2025
Trending
A Tiny Device Brings Quantum Entanglement to Room Temperature
Science · 5 min
A Louisville Restaurant Gives Away 100% of Its Profits — and Topped $100,000 in Year One
Community · 4 min
Oregon Zoo Sets a Record With 15 California Condor Chicks in One Year
Animals · 5 min
Europe Tears Down a Record 603 River Barriers, Setting Its Waters Free
Environment · 5 min
DeepMind unveils Co-Scientist, an AI research partner that already helped find a liver-disease drug candidate
Artificial Intelligence · 5 min
